Dynavax announces strategic restructuring to focus on its vaccine business
Dynavax announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. The company will explore strategic alternatives for its immuno-oncology portfolio. May 23, 2019